In this issue of Clinical Cancer Research, Wilmott and colleagues (1) report that the administration of selective BRAF inhibitors in patients with metastatic melanoma results in early infiltration of CD4þ and CD8þ T lymphocytes. The magnitude of CD8þ lymphocyte infiltration correlates with tumor shrinkage, but at the time of tumor progression the immune infiltrate is most often lost. These data are important because they support the hypothesis that immune activation plays a role in the antitumor activity of targeting the BRAF oncogene in patients.
Metastatic melanoma is a notoriously deadly malignancy, and until recently there were no therapies capable of extending patient survival. In 2011, 2 agents with different mechanisms of action were approved in the United States for use in melanoma, based on evidence that they each prolong overall survival in selected populations. Ipilimumab, a fully human monoclonal antibody, antagonizes cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) on T lymphocytes, thereby silencing a negative regulator of Tcell response. CTLA-4 blockade allows T-cell activation and leads to immune-mediated destruction of melanoma cells. When used as a single agent, the objective response rate for ipilimumab is <15%, but for a minority of patients, clinical response can be sustained long-term (2) . The selective BRAF inhibitor vemurafenib was also approved last year, and the drug has emerged as a highly active and well-tolerated treatment that improves survival for patients whose tumors harbor a BRAF mutation. (5) . The presence of intratumoral T cells is a positive prognostic biomarker in primary melanoma. This may also be the case in metastatic melanoma. Wilmott and colleagues (1) now report that selective BRAF inhibition in patients with metastatic melanoma results in a marked increase in tumor-infiltrating T cells. Although they are not addressed specifically in this study, at least 2 mechanisms could explain this immunological effect. First, tumor cell death in the wake of a therapy that is not itself overtly immunotoxic or immunosuppressive may produce a "vaccine effect" insofar as tumor antigens that are shed after therapy may be processed and presented by host antigen-presenting cells (APC) to drive tumor-specific adaptive immune responses. Second, the influx of T cells during treatment may also occur as a direct response to changes in the tumor microenvironment caused by BRAF inhibition. For example, the production of the immunomodulatory cytokines interleukin 10 (IL-10), VEGF, and IL-6 by melanoma cell lines is controlled by the mitogen-activated protein kinase (MAPK) pathway and decreased in vitro by treatment with mitogen-activated protein-extracellular signal-regulated kinase (MEK) inhibition or BRAF V600E RNA interference (6) . Thus, treatment with selective BRAF inhibitors in vivo may alter this immunosuppressive cytokine milieu and permit enhanced infiltration of T cells. In addition, dying tumor cells may also release ATP (7) and other cellular contents that act as strong chemoattractants for T cells that are not otherwise present in the tumor microenvironment. In this case, T cells may be actively recruited to regressing melanoma, as clearly shown in this study, although it remains to be shown that tumorinfiltrating T cells following BRAF inhibition are tumor specific. The key point, however, is that vemurafenib does not appear to be immunosuppressive, and in fact may promote T-cell responses by enhancing antigen presentation by tumor cells (8, 9) . Other immunological effects of BRAF inhibition on the tumor microenvironment may be highly nuanced and intertwined. For example, macrophages are generally considered to be tumor-promoting leukocytes through their roles in angiogenesis, metastasis, and production of a T-cell-suppressive microenvironment. Melanoma cell line growth in the mouse is enhanced by tumor-associated macrophages (10) , and the production of macrophage chemoattractant protein 1, the major chemokine for macrophages, is upregulated in part by the MAPK pathway (11), which suggests that its production may be decreased by selective BRAF inhibition. Understanding the role of tumorassociated macrophages in patients receiving selective BRAF inhibitors would be a valuable next step in elucidating the interplay between oncogene inhibition and the innate immune system.
The findings from Wilmott and colleagues fit nicely with the increasing body of data regarding the importance of the immune system in eradicating tumors following oncogene inactivation. Using a mouse model of T-cell acute lymphoblastic lymphoma (T-ALL) driven by the c-MYC oncogene, Rakhra and colleagues (12) showed the necessity of the immune system for eliminating tumors completely. In their study, T-ALL tumors driven by the tetracycline-sensitive c-MYC oncogene were implanted into wild-type mice or mice with various forms of lymphocyte deficiency. Tumor growth was monitored following oncogene inactivation, which was accomplished experimentally by doxycycline administration. Partial regression was seen upon c-MYC inactivation in all of the animals; however, in the absence of CD4þ T cells, tumors failed to regress completely and began to grow despite continued oncogene inactivation. The host immune system was shown to produce antitumor cytokines in the presence of c-MYC inactivation, which were necessary mediators of tumor elimination. Similar immune-mediated responses were also seen in a BCR-ABL oncogene-induced model of pro-B-cell acute lymphoblastic leukemia.
To the extent that such murine models show that an immune response is important or even required for optimal tumor regression following oncogene inactivation, strategies to add potent immunomodulatory drugs (e.g., anti-CTLA-4 mAb) to oncogene-targeted cancer therapies have merit. This is particularly true in melanoma, for which ipilimumab is clinically approved. Indeed, a phase I/II trial combining ipilimumab and vemurafenib recently began accrual. In one proposed mechanism of action ( Fig. 1) , selective BRAF inhibition blocks the activated MAPK pathway, resulting in tumor cell death by targeting (Fig. 1) , and many of these can be seen as potential partners with oncogenetargeted therapy. With the increasing development of targeted therapies for multiple types of tumors, the combination of these agents with immune therapy represents an exciting clinical frontier with a sound scientific rationale.
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